Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on September 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor presentation furnished under Regulation FD for use in discussions with investors and analysts.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation furnished under Regulation FD for use in discussions with investors and analysts
- Presentation likely provides current company messaging, pipeline context, and corporate updates
- Exhibit 99.1 contains the substantive investor-facing information
Item EX-99.1 · Exhibit EX-99.1
- September 2026 corporate presentation highlights positive Phase 3 prostate-cancer data for aglatimagene, supporting potential BLA filing in 2026
- Phase 3 trial enrolled 745 patients and achieved disease-free survival endpoint with 30% recurrence-risk reduction
- Prostate cancer-specific DFS improved 38%, with hazard ratio 0.62 and P=0.0046
- Cash and equivalents $201.6M as of June 30, 2026, supporting expected runway into Q1 2028
- Potential commercial opportunity exceeds $10B, while $100M royalty funding remains subject to prostate-cancer approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.